Search Results - "Mesa, Ruben"

Ruxolitinib by Mesa, Ruben A., Yasothan, Uma, Kirkpatrick, Peter

“…Janus kinase inhibitor approved by the US Food and Drug Administration for the treatment of myelofibrosis. In November 2011, ruxolitinib (Jakafi;…”
Get full text

Management of myelofibrosis after ruxolitinib failure by Harrison, Claire N, Schaap, Nicolaas, Mesa, Ruben A

“…Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow…”
Get full text

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis by Mesa, Ruben A, Kiladjian, Jean-Jacques, Catalano, John V, Devos, Timothy, Egyed, Miklos, Hellmann, Andrzei, McLornan, Donal, Shimoda, Kazuya, Winton, Elliott F, Deng, Wei, Dubowy, Ronald L, Maltzman, Julia D, Cervantes, Francisco, Gotlib, Jason

“…Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in…”
Get full text

The renaissance of interferon therapy for the treatment of myeloid malignancies by Kiladjian, Jean-Jacques, Mesa, Ruben A., Hoffman, Ronald

“…IFNα has been used to treat malignant and viral disorders for more than 25 years. Its efficacy is likely the consequence of its broad range of biologic…”
Get full text

How I treat symptomatic splenomegaly in patients with myelofibrosis by Mesa, Ruben A.

“…Managing patients with myelofibrosis (MF), either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential…”
Get full text

Novel strategies for challenging scenarios encountered in managing myelofibrosis by Bose, Prithviraj, Mesa, Ruben A.

“…Given its rarity, multi-faceted clinical presentation and the relative paucity of approved therapies, the management of myeloproliferative neoplasm…”
Get full text

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis by Verstovsek, Srdan, Mesa, Ruben A, Gotlib, Jason, Levy, Richard S, Gupta, Vikas, DiPersio, John F, Catalano, John V, Deininger, Michael, Miller, Carole, Silver, Richard T, Talpaz, Moshe, Winton, Elliott F, Harvey, Jimmie H, Arcasoy, Murat O, Hexner, Elizabeth, Lyons, Roger M, Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Koumenis, Iphigenia L, Sun, William, Sandor, Victor, Kantarjian, Hagop M

“…This trial showed clinically significant responses in spleen size and quality of life among patients with myelofibrosis receiving ruxolitinib, a JAK1 and JAK2…”
Get full text

Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms by Hinds, David A., Barnholt, Kimberly E., Mesa, Ruben A., Kiefer, Amy K., Do, Chuong B., Eriksson, Nicholas, Mountain, Joanna L., Francke, Uta, Tung, Joyce Y., Nguyen, Huong (Marie), Zhang, Haiyu, Gojenola, Linda, Zehnder, James L., Gotlib, Jason

“…We conducted a genome-wide association study (GWAS) to identify novel predisposition alleles associated with Philadelphia chromosome-negative…”
Get full text

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses by Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A, Vannucchi, Alessandro M, Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N, Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas

“…Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated…”
Get full text

Therapy for myeloproliferative neoplasms: when, which agent, and how? by Geyer, Holly L., Mesa, Ruben A.

“…Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized…”
Get full text

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union by Moulard, Odile, Mehta, Jyotsna, Fryzek, Jon, Olivares, Robert, Iqbal, Usman, Mesa, Ruben A.

“…Background Primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV) are BCR ABL‐negative myeloproliferative neoplasms (MPN)…”
Get full text

Management of challenging myelofibrosis after JAK inhibitor failure and/or progression by Scherber, Robyn M., Mesa, Ruben A.

“…The myeloproliferative neoplasms (MPNs) encompass a heterogenous set of diseases that have variable survival, but in the setting of treatment refractory and…”
Get full text

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis by Verstovsek, Srdan, Kantarjian, Hagop, Mesa, Ruben A, Pardanani, Animesh D, Cortes-Franco, Jorge, Thomas, Deborah A, Estrov, Zeev, Fridman, Jordan S, Bradley, Edward C, Erickson-Viitanen, Susan, Vaddi, Kris, Levy, Richard, Tefferi, Ayalew

“…The authors report on the clinical activity of a new oral inhibitor of Janus kinase 2 (JAK2) in patients with myelofibrosis. The drug improved a wide range of…”
Get full text

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment by Cervantes, Francisco, Dupriez, Brigitte, Pereira, Arturo, Passamonti, Francesco, Reilly, John T., Morra, Enrica, Vannucchi, Alessandro M., Mesa, Ruben A., Demory, Jean-Loup, Barosi, Giovanni, Rumi, Elisa, Tefferi, Ayalew

“…Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation…”
Get full text

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing by Mesa, Ruben A, Cortes, Jorge

“…Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm…”
Get full text

Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies by Verstovsek, Srdan, Kiladjian, Jean‐Jacques, Vannucchi, Alessandro M., Mesa, Ruben A., Squier, Peg, Hamer‐Maansson, J. E., Harrison, Claire

“…Background In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT‐I) and COMFORT‐II clinical trials,…”
Get full text

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet by Barbui, Tiziano, Tefferi, Ayalew, Vannucchi, Alessandro M., Passamonti, Francesco, Silver, Richard T., Hoffman, Ronald, Verstovsek, Srdan, Mesa, Ruben, Kiladjian, Jean-Jacques, Hehlmann, Rȕdiger, Reiter, Andreas, Cervantes, Francisco, Harrison, Claire, Mc Mullin, Mary Frances, Hasselbalch, Hans Carl, Koschmieder, Steffen, Marchetti, Monia, Bacigalupo, Andrea, Finazzi, Guido, Kroeger, Nicolaus, Griesshammer, Martin, Birgegard, Gunnar, Barosi, Giovanni

“…This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by…”
Get full text

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera by Vannucchi, Alessandro M, Kiladjian, Jean Jacques, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N, Pane, Fabrizio, Zachee, Pierre, Mesa, Ruben, He, Shui, Jones, Mark M, Garrett, William, Li, Jingjin, Pirron, Ulrich, Habr, Dany, Verstovsek, Srdan

“…Ruxolitinib, an oral inhibitor of Janus kinase (JAK) 1 and 2, was associated with hematocrit control and spleen size reduction in 21% of patients with…”
Get full text

Anemia in myelofibrosis: Current and emerging treatment options by Passamonti, Francesco, Harrison, Claire N., Mesa, Ruben A., Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Verstovsek, Srdan

“…Myelofibrosis (MF) is a clonal hematologic malignancy with progressive bone marrow fibrosis. Clinical manifestations of MF include splenomegaly, constitutional…”
Get full text

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure by Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean‐Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Rose, Shelonitda, Shen, Juan, Berry, Tymara, Brownstein, Carrie, Mesa, Ruben A.

“…Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate‐ or high‐risk…”
Get full text